CF Foundation grants Corbus $25M for Phase IIb study

The not-for-profit Cystic Fibrosis Foundation awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of the company's lenabasum (formerly anabasum) to treat cystic fibrosis.

The award, announced Tuesday, will provide the company with enough runway to complete the study, which will enroll CF patients ages 12 and older who are at an increased risk for pulmonary exacerbations...